MEDICAL SYSTEM NETWORK (4350) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Despite a 7.4% increase in revenue, this was a case of higher revenue but lower earnings, as profit was compressed by rising personnel expenses and a decline in patients with acute illnesses. Revenue was ¥986.8B (+7.4% YoY), Operating Income was ¥23.7B (-7.8%), Ordinary Income was ¥22.6B (-14.0%), and Net Income attributable to owners of the parent was ¥10.1B (-30.1%). In the core Regional Pharmacy Network Business, higher prescription unit prices and new store openings supported revenue growth while the number of prescriptions at existing stores declined by 2.3%; however, increased costs and an impairment loss of ¥1.4B exerted downward pressure on earnings.

Factors Affecting Earnings

【Revenue】Revenue increased 7.4% YoY to ¥986.8B. The core Regional Pharmacy Network Business led growth with revenue of ¥948.2B (+8.0%), supported by contributions from stores opened in the previous fiscal year and a +5.0% increase in prescription unit prices. Meanwhile, the number of prescriptions at existing stores declined by 2.3%, indicating a slowdown in volume growth.

【Profit and Loss】Operating Income declined 7.8% YoY to ¥23.7B, while Ordinary Income declined 14.0% to ¥22.6B. The SG&A expense ratio was 38.3%, up from approximately 35.5% in the previous year, mainly due to higher personnel expenses and lost earnings resulting from the decline in patients with acute illnesses. Extraordinary losses of ¥2.15B, including an impairment loss of ¥1.45B, further reduced profit as a temporary factor. Against Profit Before Tax of ¥20.6B, corporate income taxes and other taxes amounted to ¥10.2B, representing an effective tax rate of 49.6%, resulting in Net Income attributable to owners of the parent of ¥10.1B (-30.1%). The divergence between Ordinary Income and Net Income reached approximately 55%, reflecting the significant impact of the tax burden and extraordinary losses. In conclusion, this was an earnings result characterized by higher revenue but lower earnings.

Segment Analysis

The Regional Pharmacy Network Business generated external customer revenue of ¥948.2B and segment profit of ¥4.33B, making it the core business and accounting for approximately 96% of the revenue mix. Although the business secured revenue growth (+8.0%), segment profit declined 2.1% YoY due to higher personnel expenses and a decline in patients with acute illnesses. The Rental and Equipment-Related Business contracted, with revenue of ¥1.87B (-10.4%) and profit of ¥0.13B (-31.4%), while the Food Service Business fell into an operating loss of ¥0.09B. Corporate expenses amounted to ¥2.35B, absorbing approximately 53% of the total reported segment profit of ¥4.44B. In addition to improving profitability in the core business, reducing corporate expenses will be important for the recovery of consolidated Operating Income.

Key Financial Metrics

Profitability: ROE was 6.1%, Operating Income margin was 2.4%, and Net Income margin was 1.0%.
Cash flow quality: Operating CF was ▲¥42.8B, negative relative to Net Income of ¥10.1B, and cash backing could not be confirmed.
Financial soundness: The Equity Ratio was 20.7%, down from 23.0% in the previous fiscal year, and the current ratio was 89.5%, below 1.0x.
Per-share metrics: EPS was ¥34.56 (¥49.44 in the previous year), and BPS was ¥579.58.

Cash Flow Analysis

Operating CF deteriorated to ▲¥42.8B, creating a significant divergence from Net Income of ¥10.1B. The primary factor was an increase in trade receivables of ▲¥91.7B, resulting from the company retaining accounts receivable on its own balance sheet due to the temporary suspension of its receivables securitization scheme. Accordingly, short-term borrowings increased sharply to ¥108.7B (+¥102.9B YoY) to fund working capital. EBITDA was approximately ¥4.92B, indicating that the underlying cash-generation capacity of the core business itself has been maintained. Cash-generation performance requires monitoring, and normalization through the resumption of receivables securitization in the second half is a key issue.

Earnings Quality

The divergence between Ordinary Income and Net Income attributable to owners of the parent (¥10.1B) was attributable to the high tax burden from Profit Before Tax of ¥20.6B, with an effective tax rate of 49.6%, as well as extraordinary losses of ¥2.15B, including an impairment loss of ¥1.45B. Non-operating income was ¥0.28B, equivalent to only 0.3% of revenue, while interest expense of ¥0.24B accounted for the majority of non-operating expenses of ¥0.40B. Operating CF of ▲¥42.8B was below Net Income, indicating that current-period earnings lacked cash backing. However, the cause was a temporary liquidity adjustment resulting from the temporary suspension of receivables securitization and does not directly indicate a deterioration in business operations.

Earnings Forecast and Guidance

Progress against the full-year forecast was 78.6% for revenue, 69.8% for Operating Income, 70.5% for Ordinary Income, and 77.7% for Net Income attributable to owners of the parent. Compared with the standard progress benchmark of 75%, revenue and Net Income are ahead, while Operating Income and Ordinary Income are behind, requiring an improvement in profit margins in the second half. To achieve the full-year Operating Income forecast of ¥3.40B, approximately ¥1.03B will be required in Q4. New store openings are behind schedule at 17 stores, or 68.0%, against a plan of 25 stores, while the number of medical institutions recruited exceeded the plan at 17 against a target of 10, or 170%.

Shareholder Returns

The Q2 dividend was ¥6.00 per share, and the full-year dividend forecast is ¥12.00 per share. The Payout Ratio based solely on dividends is approximately 18.2%, based on current-period actual Net Income, indicating a low dividend burden relative to earnings. However, with Operating CF at ▲¥42.8B, the sustainability of dividends from a cash perspective requires confirmation of a normalization in Operating CF. No share repurchases have been confirmed; therefore, the company should be evaluated based on the Payout Ratio rather than the Total Return Ratio.

Catalysts

【Short Term】Normalization of cash flow through the resumption of receivables securitization and improvement in working capital in the second half, as well as progress toward the full-year new store opening plan of 25 stores.
【Long Term】Expansion of customers for the Pharmacy Support Division, including the pharmaceutical network, digital shift, manufacturing and sales, and logistics businesses, as well as the Seventh Medium-Term Management Plan scheduled to be announced in May 2026.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (retail)

Profitability and Returns

The company’s profitability is slightly below the industry median.

Growth and Capital Efficiency

Revenue growth ranks in the upper tier of the industry, but has not been accompanied by an improvement in profit margins.

※Source: Compiled by the Company

Risk Factors

1. Short-term liquidity risk: The current ratio of 89.5% is below 1.0x, while cash/short-term liabilities is only 0.75x. The refinancing terms for short-term borrowings of ¥108.7B will influence the financial burden.

2. Goodwill impairment risk: Goodwill of ¥90.6B is equivalent to 53.1% of net assets, and the company recorded an impairment loss of ¥1.45B in the current period. If the profitability of acquired businesses deteriorates, additional impairment could place pressure on shareholders’ equity.

3. Risk of declining profitability in the core business: Although the Regional Pharmacy Network Business is generating higher revenue, its profit margin has declined from approximately 2.5% to approximately 2.3%. Rising personnel expenses and a decline in patients with acute illnesses are structural sources of pressure.

Key Points from the Earnings Results

1. Revenue growth remains strong relative to the industry at +7.4%, but the Operating Income margin of 2.4% is below the industry median of 3.2%, indicating a structure in which revenue growth has become decoupled from earnings growth.

2. The deterioration in Operating CF (▲¥42.8B) was caused by an increase in trade receivables and the temporary suspension of receivables securitization. The resumption of securitization in the second half will be a key indicator for the normalization of liquidity management.

3. Corporate expenses absorbed approximately 53% of reported segment profit, making trends in corporate expense management an important factor in the recovery of the consolidated profit margin.

---

This report is an automatically generated earnings analysis document produced by AI through integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the company based on publicly available earnings data. Investment decisions should be made at your own discretion and, where necessary, after consulting with a professional advisor.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was mixed: sales expanded solidly, but profit conversion weakened and the balance sheet became more leveraged. Revenue rose 7.4% YoY to ¥98.68bn. Gross profit increased to ¥40.16bn, although the gross margin declined 85bp YoY to 40.7%. SG&A expenses rose 6.4% YoY to ¥37.79bn, modestly slower than revenue growth, reducing the SG&A ratio by 46bp to 38.3%. Nevertheless, the lower gross margin more than offset this expense leverage. Operating income fell 7.8% to ¥2.37bn and the operating margin compressed 40bp to 2.4%. Ordinary income declined 14.0% to ¥2.26bn as interest expense increased to ¥0.24bn from ¥0.20bn. Profit attributable to owners fell 30.1% to ¥1.01bn, with the net margin declining 58bp to 1.0%. The decline below ordinary income was amplified by a ¥2.15bn extraordinary loss, including ¥1.45bn of impairment, compared with a prior-year period that benefited from a ¥3.37bn gain on sales of fixed assets. The effective tax rate was 49.6%, materially above a typical corporate tax burden and a further drag on net profit. The core regional pharmacy network generated 96.1% of consolidated external revenue and remained profitable, but its segment margin declined. Consolidated operating profit was also constrained by unallocated corporate expenses, which increased 5.4% YoY to ¥2.35bn. Annualized ROE was 7.9%, supported principally by 4.83x financial leverage rather than by the 1.0% net margin. Liquidity is tight, with a 0.90x current ratio and negative working capital of ¥3.90bn. Short-term borrowings increased sharply to ¥10.87bn, elevating refinancing dependence. Goodwill of ¥9.06bn equals 53.1% of equity, leaving book value and future earnings exposed to value-retention and impairment risk. Management's full-year forecast requires a substantial Q4 operating-profit acceleration, making margin recovery and funding discipline central issues for the remainder of FY2026.

Profitability Analysis

Annualized DuPont ROE is 7.9%, decomposed into a 1.0% net profit margin, 1.598x asset turnover, and 4.83x financial leverage. The weak net margin is the limiting factor in the return profile: the 2.4% EBIT margin is below the 5% efficiency threshold, while leverage is the principal support for equity returns. Revenue growth of 7.4% did not translate into operating-income growth because gross margin fell from 41.5% to 40.7%, a decline of 85bp. SG&A rose 6.4%, below revenue growth, and the SG&A ratio improved from 38.8% to 38.3%; therefore, expense control partly cushioned, but did not reverse, gross-margin pressure. Operating margin fell from 2.8% to 2.4%, while the net margin fell from 1.6% to 1.0%. In the five-factor framework, the tax burden was only 0.489 and interest burden was 0.870, showing that elevated taxation and financing costs reduced conversion of EBIT into net income. Interest coverage remains adequate at 10.01x, but interest expense rose 17.3% YoY and is increasingly material against a narrow operating margin. The regional pharmacy network is the core business, contributing ¥94.82bn of external revenue, up 8.0% YoY, and ¥4.33bn of segment profit, down 2.1%; its segment margin declined 46bp to 4.6%. Rental and facilities revenue declined 10.4% to ¥1.87bn and segment profit declined 31.4% to ¥1.29bn. Food service revenue declined 1.9% to ¥1.73bn and recorded a ¥0.09bn segment loss, versus a marginal profit in the prior year. Other operations recorded a ¥0.11bn segment loss. Segment profit before corporate costs declined 3.4% to ¥4.44bn, while unallocated corporate expenses rose to ¥2.35bn from ¥2.23bn, explaining the sharper 7.8% decline in consolidated operating income. The low 4.5% ROIC is a material capital-efficiency concern: returns are below the 5% warning level and are insufficiently robust relative to the capital base and debt burden.

Growth Assessment

Sales growth is concentrated in the regional pharmacy network, where revenue increased ¥7.04bn YoY. This growth was sufficient to lift consolidated revenue by ¥6.79bn, despite declines in rental and facilities, food service, and other operations. However, pharmacy segment profit declined ¥0.11bn despite higher sales, indicating that current growth is less profitable at the segment level. The gross-margin decline indicates that revenue expansion has not yet produced favorable operating leverage. Full-year sales guidance is ¥125.50bn, and the Q3 cumulative achievement rate is 78.6%, 3.6 percentage points ahead of the standard 75% Q3 pace. Operating-income progress is 69.8% against the ¥3.40bn forecast, 5.2 percentage points behind the standard pace. Ordinary-income progress is 70.5% versus the ¥3.20bn forecast, also behind the standard pace. Profit attributable to owners has reached 77.7% of the ¥1.30bn forecast, helped by the fact that the forecasted remaining Q4 net income requirement is modest relative to the Q3 cumulative result. Achieving operating-income guidance requires approximately ¥1.03bn of Q4 operating income on approximately ¥26.82bn of Q4 revenue, equivalent to a 3.8% Q4 operating margin versus the 2.4% Q3 cumulative margin. The implied Q4 margin recovery is demanding and depends on restoring gross-profit conversion and containing corporate costs. The consolidation of three subsidiaries during the period may support the revenue base, but the sharp increase in receivables and short-term funding means that growth must translate into timely cash collection and sustainable margins.

Financial Health

Financial health is the principal balance-sheet constraint. The current ratio is 0.90x and the quick ratio is 0.68x, both below 1.0x; this explicitly signals a liquidity warning because current assets of ¥33.38bn do not fully cover current liabilities of ¥37.28bn. Working capital is negative ¥3.90bn. Short-term loans increased from ¥0.59bn to ¥10.87bn, while current liabilities increased ¥12.90bn YoY. This creates a meaningful maturity mismatch: cash and deposits are ¥8.15bn, equivalent to only 0.75x short-term debt, before considering trade and other current obligations. The short-term debt ratio is 40.6%, slightly above the 40% refinancing-risk threshold, so access to bank funding and rollover terms are material near-term considerations. Total interest-bearing debt is ¥26.78bn, including ¥15.90bn of long-term loans and ¥10.87bn of short-term loans. Debt-to-equity is 3.83x, well above the 2.0x aggressive-leverage threshold, and debt-to-capital is 61.1%, above the 60% concern level. The high leverage appears linked to a ¥8.10bn YoY increase in interest-bearing debt and materially raises sensitivity to earnings volatility, interest costs, and refinancing conditions. Interest coverage of 10.01x provides near-term debt-service capacity, but is less reassuring when operating margin is only 2.4%. Accounts receivable increased ¥9.37bn YoY to ¥14.42bn, inventories rose ¥1.88bn to ¥7.99bn, and accounts payable increased ¥3.28bn to ¥14.76bn. These movements expanded the operating asset base and contributed to the negative working-capital position, although higher payables partly offset the funding need. Goodwill represents 11.0% of total assets and 53.1% of equity, exceeding the 50% warning threshold. Under JGAAP, goodwill amortization reduces operating profit and net income relative to IFRS reporters, while the large goodwill balance also leaves equity vulnerable if acquired businesses underperform and require impairment. Intangible assets account for 12.2% of assets, which remains below the 20% concentration benchmark.

Notable B/S Changes

Short-term loans: +¥10.29bn (+1,749.3%) to ¥10.87bn - major increase in short-term funding, worsening rollover dependence and liquidity risk. Accounts receivable: +¥9.37bn (+185.4%) to ¥14.42bn - growth far exceeded revenue expansion, increasing collection and working-capital funding risk. Inventories: +¥1.88bn (+30.7%) to ¥7.99bn - inventory rose faster than sales, requiring monitoring of stock productivity and funding needs. Accounts payable: +¥3.28bn (+28.5%) to ¥14.76bn - supplier credit partly finances working-capital growth, but also increases reliance on trade-credit conditions. Interest-bearing debt: +¥8.10bn to ¥26.78bn - higher leverage lifted D/E to 3.83x and debt/capital to 61.1%. Total assets: +¥11.73bn to ¥82.32bn - asset expansion was concentrated in current operating assets, while equity increased by only ¥0.71bn to ¥17.06bn. Goodwill: -¥0.01bn to ¥9.06bn - the balance remains large at 53.1% of equity, maintaining material impairment sensitivity.

Cash Flow Quality

The balance-sheet movement points to heightened working-capital absorption risk. Trade receivables increased 185.4% YoY to ¥14.42bn, substantially outpacing the 7.4% increase in revenue. Inventories increased 30.7% to ¥7.99bn, also faster than sales growth. The concurrent increase in accounts payable of 28.5% to ¥14.76bn provides some supplier-financing offset, but does not eliminate the collection and inventory-management risk. The combination of receivable growth, inventory growth, negative working capital, and sharply higher short-term loans indicates that operating expansion has increased funding requirements. Accordingly, earnings conversion should be monitored through receivable collection, inventory discipline, and the dependence on supplier credit. The ¥1.45bn impairment loss is a non-cash extraordinary charge, but it signals that part of the asset base has already failed to meet prior carrying-value assumptions. The current period's net income is also affected by non-recurring extraordinary losses of ¥2.15bn, whereas the prior period benefited from ¥3.37bn of gains on sales of fixed assets; underlying operating performance is therefore better assessed from operating and ordinary income, both of which still declined YoY.

Dividend Sustainability

The company paid an interim Q2 dividend of ¥6.00 per share. Full-year guidance indicates DPS of ¥12.00, implying an expected dividend-only payout ratio of approximately 27.0% based on forecast EPS of ¥44.48. This is below the 60% sustainability benchmark and leaves an accounting earnings buffer. The interim ¥6.00 dividend represented 18.2% of Q3 cumulative net income on the stated calculation. However, dividend resilience is constrained more by liquidity and leverage than by the indicated payout ratio. Negative working capital, a 0.90x current ratio, and ¥10.87bn of short-term borrowings mean that capital allocation must remain consistent with refinancing and operating-funding needs. The maintenance of the ¥12.00 full-year dividend outlook depends on delivery of the forecast earnings recovery and disciplined balance-sheet management.

Risk Assessment

Business risks include Margin risk in the regional pharmacy network: core segment revenue rose 8.0% YoY but segment profit fell 2.1%, reducing its margin to 4.6%., Gross-profit pressure: consolidated gross margin contracted 85bp YoY, and this was the main reason operating income declined despite revenue growth., Q4 execution risk: full-year operating-income guidance requires an implied Q4 operating margin of approximately 3.8%, materially above the 2.4% Q3 cumulative margin., Food service and other-business profitability risk: both businesses recorded segment losses in the current period., Industry-specific pharmacy risk: reimbursement conditions, drug pricing, dispensing-volume mix, and labor availability can pressure gross profit and pharmacy operating margins..

Financial risks include Low liquidity: the 0.90x current ratio and 0.68x quick ratio indicate that short-term liabilities exceed readily realizable current assets., High leverage: D/E of 3.83x and debt/capital of 61.1% imply aggressive debt financing and amplify downside risk from modest earnings changes., Refinancing risk: short-term debt is 40.6% of interest-bearing debt and cash covers only 0.75x of short-term loans., Interest-cost risk: interest expense increased to ¥0.24bn and the interest burden of 0.870 shows that debt costs are already reducing pre-tax profit conversion., Goodwill risk: goodwill of ¥9.06bn equals 53.1% of equity, so impairment or weak acquired-business performance could materially affect equity and earnings., Capital-efficiency risk: 4.5% ROIC is below the 5% warning threshold and suggests limited return headroom after considering the capital employed..

Key concerns include High likelihood/high impact: liquidity and refinancing discipline, given negative ¥3.90bn working capital, the surge in short-term loans, and low cash coverage of short-term debt., High likelihood/high impact: ability to restore operating margin sufficiently to meet full-year operating-income guidance., Medium likelihood/high impact: goodwill value retention, particularly following a current-period ¥1.45bn impairment charge., Medium likelihood/medium impact: receivable and inventory growth outpacing revenue, which can increase funding needs and weaken earnings conversion., Medium likelihood/medium impact: the 49.6% effective tax rate, which materially reduced net-income conversion and may remain a drag if not normalized..

Investment Implications

Key takeaways include Revenue growth remains positive and the pharmacy network is the dominant earnings engine, but core segment profitability has weakened., The 2.4% operating margin, 1.0% net margin, and 4.5% ROIC indicate low operating and capital efficiency., Annualized ROE of 7.9% is largely leverage-supported, with 4.83x financial leverage offsetting weak profitability., Balance-sheet risk increased materially as short-term borrowings rose ¥10.29bn YoY and D/E reached 3.83x., Full-year sales guidance appears attainable on Q3 progress, while operating-profit guidance requires a significant Q4 margin improvement..

Metrics to watch include Regional pharmacy network segment margin and consolidated gross margin, Q4 operating income versus the ¥1.03bn implied requirement, Accounts receivable collection and inventory levels relative to sales, Short-term loan balance, cash-to-short-term-debt coverage, and current ratio, Interest expense and interest coverage, Goodwill balance, impairment charges, and ROIC.

Regarding relative positioning, The company combines a defensible scale revenue base in regional pharmacy operations with below-benchmark profitability and capital efficiency. Its 40.7% gross margin is high in absolute terms, but the 38.3% SG&A ratio leaves only a 2.4% operating margin. Relative financial positioning is weakened by 3.83x D/E, sub-1.0x liquidity ratios, and goodwill exceeding half of equity; these factors make execution and balance-sheet management more important than topline growth alone.